Pages that link to "Q61832236"

The following pages link to Long-Term Results of Melphalan-Based Isolated Limb Perfusion With or Without Low-Dose TNF for In-Transit Melanoma Metastases (Q61832236):

Displaying 10 items.

• Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha (Q33768595) (← links)
• 20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters (Q34006197) (← links)
• Current treatment of locoregional recurrence of melanoma (Q34888462) (← links)
• The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options (Q36102807) (← links)
• Melanoma m (zero): diagnosis and therapy (Q36830323) (← links)
• Melanoma Immunotherapy (Q37812066) (← links)
• Death receptors as targets in cancer (Q38103591) (← links)
• Normal human CD4(+) helper T cells express Kv1.1 voltage-gated K(+) channels, and selective Kv1.1 block in T cells induces by itself robust TNFα production and secretion and activation of the NFκB non-canonical pathway. (Q40892979) (← links)
• Subcutaneous metastases from melanoma: a discussion of clinical experience (Q56896770) (← links)
• Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion (Q131416766) (← links)